Skip to content

More Than a Machine: Make Point-of-care HIV-1 Viral Load Testing Effective in Rural Uganda

IGHID 11920 - More Than a Machine: Exploring the Ancillary Systems and Processes Required to Make Point-of-care HIV-1 Viral Load Testing Effective in Rural Western Uganda

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04517825
Enrollment
242
Registered
2020-08-18
Start date
2020-08-08
Completion date
2021-06-30
Last updated
2022-05-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV-1-infection

Keywords

viral load, CD4

Brief summary

This is a two-phase study designed to assess measures of feasibility, sustainability, acceptability, penetration, and fidelity before and after implementation of a rapid molecular HIV-1 viral load testing infrastructure at a level III health center in rural western Uganda. The central hypothesis is that implementation of PoC HIV-1 testing without accompanying modifications to clinic triage and flow, laboratory processes, and existing protocols guiding adherence counseling and regimen change, will not result in significant improvement in clinical outcomes in PLWH.

Detailed description

This is a two-phase study designed to assess measures of feasibility, sustainability, acceptability, penetration, and fidelity before and after implementation of a rapid molecular HIV-1 viral load testing infrastructure at a level III health center in rural western Uganda. In Phase 1, the study team will perform/record the following: 1. Administer a basic demographic and health questionnaire 2. Record routine clinical parameters during visit to include: 1. Current ARV and prophylaxis regimen 2. Last CD4 and VL, if available 3. Clinical illness since last visit 3. Document the amount of time each patient spends in each phase of clinic (i.e. waiting room, provider, phlebotomy, waiting for results, adherence counseling). 4. Measure the number of participants requiring HIV-1 VL testing each clinic day, proportion electing to receive results by phone or at next visit. 5. Patients having blood drawn for HIV-1 VL testing will complete a semi-structured interview to explore perceptions of the current testing paradigm when results are received. 6. Provider and laboratory staff will complete a semi-structured interview to explore perceptions of the current testing paradigm with emphasis on workload In Phase 2, the study team will perform/record the following: 1. Record routine clinical parameters during visit to include: 1. Current ARV and prophylaxis regimen 2. Last CD4 and VL, if available 3. Clinical illness since last visit 2. Determine the amount of time each patient spends in each phase of clinic (i.e. waiting room, provider, phlebotomy, waiting for results, adherence counseling). 3. Measure the number of Xpert HIV-1 tests performed, the amount of time laboratory staff spends performing the tests and conducting maintenance, the number of tests failures and/or invalid tests, and equipment downtime related problems with software or power supply. 4. Measure the number of participants requiring HIV-1 VL testing each clinic day, proportion electing to receive results on same day, by phone, or next visit. 5. Patients having blood drawn for HIV-1 VL testing will complete a semi-structured interview to explore perceptions of the current testing paradigm when results are received. 6. Provider and laboratory staff will complete a semi-structured interview to explore perceptions of the current testing paradigm with emphasis on workload.

Interventions

DIAGNOSTIC_TESTCepheid Xpert HIV-1 Viral Load Assay

Rapid, on-site molecular HIV-1 viral load testing used in accordance with cleared/approved labeling

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)
CollaboratorNIH
University of North Carolina, Chapel Hill
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult patients aged 18 years or older receiving care at the Bugoye Health Center Antiretroviral therapy clinic

Exclusion criteria

* Patients unwilling or unable to provide informed consent

Design outcomes

Primary

MeasureTime frameDescription
Number of Tests Performed Successfully Each Clinic DayEach clinic day for up to six monthsHIV viral load tests performed at peripheral health center
Number of Tests Performed Successfully each MonthEach month for up to six monthsHIV viral load tests performed at peripheral health center

Secondary

MeasureTime frameDescription
Provider Perception of WorkloadPre- and post-intervention (approximately 6 months apart)Perceived time spent conducting on-site testing vs send-out testing
Proportion of Eligible Patients Electing to Stay to Receive ResultsEach clinic day for up to six monthsAcceptability of rapid HIV viral load results
Machine Down-Time and MaintenanceEach clinic day (i.e. weekly) during the 6 months of Phase 2 when the Xpert is operationalTotal number of hours spent in maintenance, trouble-shooting, or repair
Mean and median time-to-resultUp to 90 days after blood draw, after which considered not returnedMean and median number of days from blood draw to client receiving viral load result either from current standard of care or on-site testing
Mean Time Clients Spend in ClinicEach clinic day for up to 9 monthsImpact on routine ART Clinic flow

Countries

Uganda

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 9, 2026